SCHEMBL4922746

SCHEMBL4922746

CCOP(=O)(OCC)C(C(=O)OC(C)(C)C)C(C)C

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HMGCR P04035 2/20 0.34
POLB P06746 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
ABCB1 P08183 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPT P10636 1/20 0.32
TSHR P16473 1/20 0.31
EPHX2 P34913 1/20 0.31
THRB P10828 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31010369 0.85 GAA (0.35) GAACYP3A4CYP2C9CYP2C19HMGCR
SCHEMBL30049340 0.84 GAA (0.38) GAACYP3A4CYP2C9CYP2C19HMGCR
SCHEMBL1239332 0.83 GAA (0.37) GAACYP3A4CYP2C9CYP2C19HMGCR
SCHEMBL1278020 0.82 GAA (0.40) GAACYP3A4CYP2C9CYP2C19HMGCR
SCHEMBL3163528 0.82 GAA (0.38) GAACYP3A4CYP2C9CYP2C19POLB
SCHEMBL1954818 0.80 GAA (0.41) GAACYP3A4CYP2C9CYP2C19POLB
SCHEMBL16659375 0.77 MAPT (0.43) GAAPOLBCA1CA2SMN1; SMN2
SCHEMBL5575508 0.77 CYP3A4 (0.38) GAACYP3A4CYP2C9CYP2C19HMGCR
SCHEMBL16979607 0.77 CYP3A4 (0.38) GAACYP3A4CYP2C9CYP2C19HMGCR
SCHEMBL8104064 0.77 CYP3A4 (0.45) GAACYP3A4CYP2C9CYP2C19HMGCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100439345-C (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexylmethoxy acetic acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis. SANNOFFE AVENTIS PHARMA GMBH (DE) 2008-12-03 CN disclosed
US-20080015238-A1 CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-01-17 US disclosed
US-20080015238-A1 CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-01-17 US disclosed
US-20080015238-A1 CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-01-17 US disclosed
US-7259177-B2 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-21 US disclosed
US-7259177-B2 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-21 US disclosed
US-7259177-B2 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-21 US disclosed
EP-1599452-B1 3-(2-PHENYL-OXAZOL-4-YL METHOXY) CYCLOHEXYLMETHOXY ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS USED AS PPAR MODULATORS FOR TREATING TYPE 2 DIABETES AND ARTERIOSCLEROSIS SANOFI AVENTIS DEUTSCHLAND (DE) 2007-06-20 EP disclosed
CN-1753879-A 3- (2-phenyl-oxazol-4-ylmethoxy) cyclohexyl methoxyacetic acid derivatives and related compounds as PPAR modulators for the treatment of type 2 diabetes and atherosclerosis SANNOFFE AVENTIS PHARMA GMBH (DE) 2006-03-29 CN disclosed
US-20050101637-A1 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015238-A1 CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS GPR119, PC, ACADM GAA 100/4885CYP3A4 311/4885CYP2C9 322/4885
US-20050101637-A1 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals GPR119, PC, CPT1A GAA 149/4885CYP3A4 244/4885CYP2C9 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.